The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A significant proportion of Australian children are at health risk due to environmental metal exposure. It is suspected that exposure to metals during the prenatal period can result in permanent impairment. Human studies are, however, limited by lack of biomarkers that accurately measure exposure at specific times of intrauterine development. We are proposing to develop a novel method that utilizes human primary teeth to provide a direct measure of metal exposure during foetal development.
The Molecular Basis For Manganese Uptake By Pathogenic Bacteria.
Funder
National Health and Medical Research Council
Funding Amount
$632,949.00
Summary
Bacterial antimicrobial resistance is an increasing threat to human health. At this point in time, there is an urgent, fundamental need for the development of new antimicrobial strategies. Bacterial infection involves a constant tug-of-war between the pathogen and the human host for the essential nutrients of life, including trace metal nutrients such as Mn. This project seeks to understand the machinery for Mn uptake by pathogenic bacteria as a target for novel antibacterial design.
Mechanism Of Action Of A Quinazolinone In Models Of PD
Funder
National Health and Medical Research Council
Funding Amount
$667,548.00
Summary
By the time symptoms of Parkinson's disease (PD) appear, 60-70% of the cells in a crucial part of the brain called the substantia nigra have been destroyed and within a few years of diagnosis, most of the remaining cells have died. This project investigates the causes of this cell loss and a how a new class of compounds could interrupts the process. Success in achieving the aims of this proposal will add to our knowledge of the causes of neuronal death in PD
Copper-ionophores As A Treatment For Prostate Cancer?
Funder
National Health and Medical Research Council
Funding Amount
$314,154.00
Summary
The overarching aim of this project is to evaluate a potential therapy for prostate cancer, which targets a distinct characteristic of the disease 'elevated copper'. Our copper-based drugs in the laboratory selectively destroy cancerous prostate cells without harming normal cells. We will verify whether these drugs work in the body where the environment is more complex. Proof of this principle will open up a new area of research and provide a novel therapeutic approach for prostate cancer.
What Are The Clinical Predictors And Risk Factors For Impaired Child Growth And Development? Following Up The Ha Nam Cohort From Birth To 3 Years
Funder
National Health and Medical Research Council
Funding Amount
$1,189,570.00
Summary
Stunting affects about one third of children under five in developing countries and is a measure of chronic undernutrition. This project will identify pre and postnatal risk factors for impaired child growth and development by monitoring a cohort of infants in Vietnam to three years of age, and developing a predictive algorithm for early detection of those at risk of stunting. Effective preventative measures would improve child health, and prevent a huge burden of disease.
A Randomized Controlled Trial Of Three Treatments For Anorexia Nervosa In Adults
Funder
National Health and Medical Research Council
Funding Amount
$606,447.00
Summary
This study will be the first to evaluate three promising new treatments for anorexia nervosa (AN) and anorexic type eating disorders in adults. The first treatment is a new therapy called Enhanced Cognitive Behaviour Therapy. The second treatment, the Maudsley Cognitive Motivational Therapy, was designed specifically to treat AN and the third treatment is called non-specific supportive clinical management. The study will be in the form of a multi-centre randomised treatment trial.